CION Ameerpet
A dysgerminoma is a malignant germ cell tumour of the ovary — and almost everything written about “ovarian cancer” describes a different disease in a much older woman. This one mostly affects teenagers and women in their twenties, is usually still confined to one ovary when it is found, and responds to treatment better than almost any other cancer. In nearly every case the uterus and the other ovary stay where they are.
A dysgerminoma is a malignant tumour that arises from the ovary's germ cells — the primordial cells that would otherwise have become eggs. That single fact separates it from almost everything you will read about ovarian cancer, because the common ovarian cancers begin in the surface lining of the ovary and fallopian tube, not in the germ cells. It is the commonest malignant ovarian germ cell tumour, and it is the direct ovarian counterpart of testicular seminoma. Much of what is known about treating it comes from that shared biology.
It affects a different group of people, too. Dysgerminoma turns up mostly in teenagers and women in their twenties, sometimes in girls before their periods have started, and it is the ovarian cancer most often diagnosed during pregnancy. So when you search and find survival figures, risk factors and treatment descriptions aimed at women over 50 — the general ovarian cancer guide included — very little of it is describing this. BRCA, family history and reproductive history, which dominate the conversation about epithelial ovarian cancer, have no established link with dysgerminoma at all.
Now the part that matters most on the day of diagnosis. This is cancer and it is treated seriously. It is also one of the most treatable cancers in medicine. It is usually still confined to one ovary when it is found, it is exquisitely sensitive to chemotherapy, and the uterus and the opposite ovary are left in place in almost every case — including in most women whose disease has already spread. Long-term outcomes are excellent, and the great majority of young women go on to have periods, and children, afterwards.
A different cell of origin, a different age group, a different treatment plan and a very different outlook. Most general ovarian cancer information does not apply here.
Dysgerminoma is the ovarian equivalent of seminoma. The two share biology, markers and a treatment evidence base built over decades.
Most are still confined to a single ovary when found, which is why fertility-sparing surgery is standard rather than exceptional.
Dysgerminoma is the commonest malignant germ cell tumour of the ovary, and it behaves quite unlike the ovarian cancer most information describes. Roughly two-thirds to three-quarters are FIGO stage I — still confined to one ovary — when they are found, and it is the one ovarian germ cell tumour that involves both ovaries in a meaningful minority of cases, which is why the opposite ovary is inspected at surgery rather than assumed to be clear. It is also exquisitely sensitive to both chemotherapy and radiotherapy. That sensitivity is the reason fertility-sparing surgery followed by a short course of platinum-based chemotherapy replaced the extensive surgery and pelvic radiotherapy of earlier decades. Source: WHO Classification of Tumours — Female Genital Tumours (5th ed.); NCCN Guidelines for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer.
The pathology report names one member of a small family, and the marker pattern usually tells you which before the report arrives. The differences change what treatment follows.
| Tumour | Typical age | Marker pattern | What it usually means |
|---|---|---|---|
| Dysgerminoma | Teens and twenties | LDH characteristically raised; beta-hCG sometimes mildly raised; AFP normal | Highly chemosensitive. Usually confined to one ovary. Fertility-sparing surgery is standard. |
| Yolk sac tumour | Children and young women | AFP raised, often markedly; LDH may be normal | Faster growing. Chemotherapy after surgery is standard even in early-stage disease. |
| Immature teratoma | Teens and twenties | AFP occasionally mildly raised; LDH usually normal | Graded 1 to 3. The grade, more than the stage, decides whether chemotherapy follows surgery. |
| Mixed germ cell tumour | Teens and twenties | Depends on the components present — a raised AFP alongside dysgerminoma-like histology is the giveaway | Treated according to its most aggressive component, not according to the dysgerminoma part. |
| Mature cystic teratoma (dermoid) | Any age, commonest in the reproductive years | Markers normal | Benign. Removed surgically, and no chemotherapy is needed. |
| Epithelial ovarian cancer | Usually over 50 | CA-125 may be raised; germ cell markers normal | A different disease entirely. Almost all general ovarian cancer information describes this one. |
*A raised AFP is the single most useful discriminator on the list. A pure dysgerminoma does not produce AFP, so an elevated level means a mixed germ cell tumour until proven otherwise — and that changes the treatment plan. More on what each result means in germ cell tumour markers.
The sequence is short and reasonably predictable. Most of it happens within a week or two, and most of it is done before any decision about chemotherapy is made.
Three germ cell markers are checked, along with a pregnancy test. LDH is the one characteristically raised in dysgerminoma and is the marker most often used to follow it afterwards. Beta-hCG may be mildly raised where the tumour contains syncytiotrophoblastic giant cells, and it is also raised in pregnancy — hence the pregnancy test first, which is not an assumption about you but a step that stops a result being misread.
AFP is the important one. A pure dysgerminoma does not produce AFP. If AFP is raised, the tumour almost certainly contains another germ cell component, most often yolk sac tumour, and that changes what treatment is needed. These markers are taken before surgery because a pre-operative baseline is what makes the post-operative fall interpretable. A fuller explanation is on the germ cell tumour markers page.
Pelvic ultrasound comes first and often gives the strongest clue: a solid, well-defined, rapidly grown mass in a young woman. A CT scan of the chest, abdomen and pelvis then establishes whether anything has spread beyond the ovary, particularly to the lymph nodes along the great vessels, which is the route dysgerminoma tends to take. An MRI is sometimes used instead where radiation dose in a young patient is a concern.
What is generally not done is a needle biopsy through the abdominal wall. Where a germ cell tumour is suspected the mass is removed intact, because puncturing or spilling it can seed tumour cells into the abdomen and raise the stage. This can feel like the team skipping a step; it is the opposite. The diagnosis is made on the whole specimen after it is removed.
In a girl who has not yet started her periods, or a young woman with primary amenorrhoea or delayed puberty, a karyotype is usually requested. The reason is specific: dysgerminoma can arise within a dysgenetic gonad that carries Y chromosome material, often from a pre-existing gonadoblastoma. Conditions in this group include 46,XY gonadal dysgenesis and some variants of Turner syndrome.
If Y material is found, the recommendation is generally to remove the opposite gonad as well, because a dysgenetic gonad carrying Y material has a real risk of developing a tumour of its own. That is a hard conversation to have with a young woman and her family, and it deserves proper time rather than a line on a discharge summary. It is also why the test is requested early — so that a single operation can settle it, rather than a second one later.
FIGO staging is the same system used for all ovarian cancers: stage I is confined to the ovary or ovaries, stage II has spread within the pelvis, stage III involves the abdominal cavity or its lymph nodes, and stage IV means spread further afield. Most dysgerminomas are stage I when found. Where spread has occurred, the lymph nodes along the great vessels are the commonest site.
The crucial difference from epithelial ovarian cancer is what the stage predicts. In epithelial disease, a stage III diagnosis substantially changes the outlook. In dysgerminoma, the tumour's sensitivity to chemotherapy is so marked that advanced disease is still usually curable, and fertility-sparing surgery is still usually appropriate. Stage decides how much treatment you need. It does not carry the meaning here that it carries elsewhere.
The report should state whether this is a pure dysgerminoma or a mixed germ cell tumour, and if mixed, which components are present and in what proportion. It should describe whether the capsule of the ovary was intact, whether tumour was found on its surface, and what the peritoneal washings showed — all of which feed the stage. The presence of syncytiotrophoblastic giant cells is worth noting, because it explains a mildly raised beta-hCG.
If anything on the report is unclear, ask for it to be explained rather than working from the summary line. A pure dysgerminoma and a mixed tumour containing a dysgerminoma component are managed differently, and that distinction is the single most consequential thing on the page. A second opinion on the slides is reasonable where the diagnosis was made at a centre that sees few of these.
Most of what a worried family needs on day one is not another test. It is forty-five minutes with someone who can say plainly what this tumour is, what surgery is needed, whether chemotherapy follows, and what happens to fertility.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the scan and the pathology report — most of the questions that actually matter can be answered in one sitting.
Treatment is built around one governing fact: this tumour responds so well to chemotherapy that the surgery does not have to be extensive. Almost everything below follows from that.
Standard surgery is removal of the involved ovary and its fallopian tube, leaving the uterus and the opposite ovary in place. This is not a compromise made for the sake of fertility at the cost of outcome; it is standard management for dysgerminoma, and it holds in most women even where disease has spread beyond the ovary. Surgery of this kind is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — CION arranges it with the surgical team rather than performing it in-house, and we would rather say that at the start.
Dysgerminoma is the one ovarian germ cell tumour that involves both ovaries in a meaningful minority of cases, so the opposite ovary is examined at surgery and biopsied if it looks abnormal. A normal-looking opposite ovary is not removed. The exception is where a karyotype has shown Y chromosome material, in which case removing both gonads is usually advised because the remaining one carries its own tumour risk.
Peritoneal washings are taken, the abdominal surfaces and diaphragm are inspected, and the lymph nodes along the great vessels are assessed or sampled, since that is where dysgerminoma travels first. This staging is what decides whether chemotherapy follows, so it is worth doing properly the first time. Incomplete staging is the commonest reason a young woman ends up having a second procedure or receiving treatment she might not have needed.
A fully staged stage IA dysgerminoma that has been completely removed can often be followed with close surveillance instead of chemotherapy — frequent examination, LDH and imaging — on the understanding that if it does come back, it is still treatable. Beyond that, a short course of platinum-based combination chemotherapy is standard, and it is markedly effective. Chemotherapy is delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh. Radiotherapy, which this tumour is also very sensitive to, has largely been abandoned in young women because chemotherapy achieves the same result without irradiating the pelvis. More on ovarian cancer treatment in Hyderabad.
Most young women resume normal periods after treatment and are able to conceive naturally, because the uterus and one ovary have been kept and the chemotherapy course is short. That is the usual outcome, not the optimistic one. Even so, the conversation belongs before the first cycle rather than after the last: fertility preservation is worth discussing where both ovaries are involved, where a longer course is planned, or simply where you want the extra insurance.
Relapse, when it happens, happens early — usually within the first two years — and it is generally still curable, which is why follow-up is intensive at the start and eases off afterwards. It combines clinical examination, LDH and periodic imaging. Longer term, follow-up shifts towards the things that matter to a woman in her twenties and thirties: ovarian function, periods, planning a pregnancy, and the late effects of chemotherapy.
Where you are treated matters more than usual with an uncommon tumour in a young patient. Dysgerminoma is uncommon enough that many centres see only a handful, and the decisions that go wrong tend to be the early ones — a mass punctured rather than removed intact, staging left incomplete, or an ovary removed that did not need to be. See the wider picture in our guide to germ cell ovarian tumours in young women.
The person reading this is usually seventeen to thirty, often with a parent reading over her shoulder, and the diagnosis has landed in the middle of exams, or a first job, or plans that assumed a straightforward year. What is needed on day one is rarely another test. It is someone with the time to explain what this tumour is, what the surgery involves, whether chemotherapy follows, and what happens to fertility — in that order, and without hedging.
Your first consultation at CION is free and runs to about 45 minutes. Bring the scan and the pathology report. Every case that raises a question is discussed at a tumour board rather than settled by one doctor, which matters more here than it does for common cancers, precisely because dysgerminoma is uncommon and the early decisions are the consequential ones.
We are equally plain about who does what. Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, along with nutrition support, survivorship care and follow-up, and genetic counselling where the picture calls for it. Fertility-sparing surgery and surgical staging are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. CION arranges that surgery and stays involved through it; we do not perform it ourselves, and you should hear that from us rather than discover it at admission.
One word on the numbers, because you will have looked them up. CION publishes its own one-year survival for ovarian cancer alongside the national figure: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. Both are one-year figures across an entire treated population, not cure rates and not predictions for any individual — and both are dominated by epithelial ovarian cancer in women over 50, which is a different disease from yours with a very different natural history. Published ovarian cancer statistics understate the outlook for dysgerminoma considerably. The figures worth discussing are the ones your oncologist can give you for this tumour, at your stage.
Free, unhurried, and long enough to get through surgery, chemotherapy and fertility in one sitting rather than three visits.
Multidisciplinary review, which counts for more with an uncommon tumour where the early decisions are the ones that stick.
Delivered by CION across Telangana and Andhra Pradesh, so treatment and follow-up can happen near where you live.
Fertility-sparing and staging surgery is arranged with specialist gynaecologic-oncology partner centres and may be billed there.
*One-year survival rates across all ovarian cancer types and stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Both are dominated by epithelial ovarian cancer and describe groups rather than individuals — discuss the outlook for a dysgerminoma specifically with your treating oncologist.
A dysgerminoma is a malignant tumour arising from the germ cells of the ovary — the primordial cells that would otherwise have become eggs — rather than from the surface lining, where the common ovarian cancers begin. It is the commonest malignant ovarian germ cell tumour and is the direct ovarian counterpart of testicular seminoma, sharing much of its biology and evidence base. It occurs mainly in teenagers and women in their twenties, sometimes in girls before their periods have started, and it is the ovarian cancer most often diagnosed during pregnancy. It usually presents as a rapidly enlarging pelvic mass rather than as vague long-standing symptoms, and serum LDH is characteristically raised.
Dysgerminoma is among the most treatable cancers in medicine, and the outlook is generally excellent — including for women whose disease has spread beyond the ovary, because the tumour is so sensitive to platinum-based chemotherapy. Most are still confined to one ovary when found, which helps further. Relapse, when it occurs, is usually early and usually still treatable. Be careful with the survival figures you find online for ovarian cancer: they are overwhelmingly driven by epithelial ovarian cancer in women over 50, a different disease with a different natural history, and they understate the outlook for dysgerminoma considerably. The prognosis worth discussing is the one your oncologist can give you for this tumour, at your stage, after surgery and staging are complete.
Treatment starts with surgery to remove the affected ovary and its fallopian tube, leaving the uterus and the opposite ovary in place, together with proper staging of the abdomen. That surgery is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. A completely removed, fully staged early-stage dysgerminoma can often be followed with close surveillance instead of further treatment. Otherwise a short course of platinum-based combination chemotherapy follows, which CION delivers in-house across more than 35 centres. Radiotherapy was used historically, because this tumour is very radiosensitive, but it has largely been dropped in young women since chemotherapy achieves the same result without irradiating the pelvis.
In most cases, yes. Standard surgery removes only the affected ovary and tube and leaves the uterus and the opposite ovary in place — and that holds even for many women whose disease has spread, because chemotherapy does the rest of the work. Chemotherapy for dysgerminoma is a short course, and most young women resume normal periods afterwards and conceive naturally. That is the usual outcome rather than the hopeful one. Fertility preservation is still worth discussing before treatment begins, particularly if both ovaries are involved, if a longer course of chemotherapy is planned, or simply if you want the additional security. Have that conversation before the first cycle rather than after the last.
Three markers are checked, plus a pregnancy test. LDH is characteristically raised in dysgerminoma and is the marker most often used to follow it during and after treatment. Beta-hCG can be mildly raised where the tumour contains syncytiotrophoblastic giant cells, and is also raised in pregnancy, which is why the pregnancy test comes first. AFP is the decisive one: a pure dysgerminoma does not produce AFP at all, so a raised level means the tumour almost certainly contains another germ cell component, usually a yolk sac element, and that changes the treatment plan. This is why all three are taken before surgery, so there is a baseline to measure the fall against.
The first consultation is free and runs to about 45 minutes — bring the scan and the pathology report, since the distinction between a pure dysgerminoma and a mixed germ cell tumour changes the plan. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, alongside nutrition support, survivorship care and follow-up, and genetic counselling where the picture calls for it. Fertility-sparing surgery and surgical staging are coordinated with specialist gynaecologic-oncology partner centres and may be billed there; CION arranges the surgery and stays involved through it rather than performing it in-house. Every case is reviewed at a tumour board, which matters with an uncommon tumour where the early decisions carry the most weight.